Literature DB >> 12187077

Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines.

Akihisa Kiyota1, Satoru Shintani, Mariko Mihara, Yuuji Nakahara, Yoshiya Ueyama, Tomohiro Matsumura, Tetsuhiko Tachikawa, David T W Wong.   

Abstract

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human oral squamous cell carcinoma (SCC). Recently, the link between EGFR signaling and the cell cycle has been identified. Some reports have described that EGFR-blocking monoclonal antibody 225 (mAb225) induced G1 arrest and inhibited the growth of various cancer cells. The purpose of this study was to evaluate the effect of mAb225 on human oral SCC cell lines. Exposure to mAb225 in culture inhibited the growth of oral SCC cell lines in an EGFR number-independent manner, with the percent inhibition ranging from 13.8 to 76.6%. Flow-cytometric analysis demonstrated that treatment with mAb225 induced cell accumulation in G1 phase, accompanied by a decrease in the percentage of cells in the S phase. Apoptosis was not seen in this study. G1 arrest was accompanied by a decrease in CDK2-, CDK4-, and CDK6-associated histone H1 kinase activities, and an increase in the expression levels of cell cycle inhibitors p27(KIP1) and p15(INK4B). These results suggested that the antiproliferative effect of EGFR blockade by mAb225 in oral SCC may be mediated by p27(KIP1) and p15(INK4B). Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187077     DOI: 10.1159/000065726

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  17 in total

Review 1.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors:  Hyunbo Shim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

2.  Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.

Authors:  Takashi Yamatodani; Lars Ekblad; Elisabeth Kjellén; Anders Johnsson; Hiroyuki Mineta; Johan Wennerberg
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-24       Impact factor: 4.553

3.  Effect of cetuximab treatment in squamous cell carcinomas.

Authors:  Marika Nestor
Journal:  Tumour Biol       Date:  2010-02-24

Review 4.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

5.  Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.

Authors:  D Ma; Q Fang; P Wang; R Gao; J Sun; Y Li; X Y Hu; J S Wang
Journal:  Gene Ther       Date:  2015-02-05       Impact factor: 5.250

Review 6.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Barbara A Burtness
Journal:  Clin Adv Hematol Oncol       Date:  2008-10

7.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

8.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

Review 9.  EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Paul M Harari
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

10.  Cetuximab in the management of colorectal cancer.

Authors:  Heinz-Josef Lenz
Journal:  Biologics       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.